Views
1287 of 1287 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 ARCE Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | ARD103Phase 1/2 · Acute Myeloid Leukemia | Oct 2028ARD103 · Phase 1/2 |
 ARS Pharmaceuticals, Inc.SPRY · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record |
 ATOSSA THERAPEUTICS, INC.ATOS · Nasdaq | 1 asset: 1 Ph 2 | (Z)-endoxifenPhase 2 · HR+/HER2- Metastatic Breast CancerPartial signal | Nov 2026(Z)-endoxifen · Phase 2 |
 Aardvark TherapeuticsPrivate | 1 asset: 1 Ph 3 | ARD-101Phase 3 · ObesityPartial signal | None on record |
 AbelZeta Pharma, Inc.Private | 1 asset: 1 Ph 2 | Trovocabtagene autoleucel (C-CAR088)Phase 1/2 · Multiple MyelomaWeak signal | None on record |
 AbivaxABVX · Nasdaq | 1 asset: 1 Ph 3 | obefazimodPhase 3 · Ulcerative ColitisReliable signal | Dec 2026obefazimod · Phase 2 |
 Accord BioPharma Inc.Private | 1 asset: 1 approved | Approved assets only | None on record |
| 1 asset: 1 Ph 2 | AC-101Phase 2 · Ulcerative Colitis | None on record | |
 Aclaris TherapeuticsACRS · Nasdaq | 1 asset: 1 other | ATI-052Atopic Dermatitis | None on record |
 Acrotech BiopharmaPrivate | 1 asset: 1 approved | Approved assets only | Dec 2026difamilast · Phase 3 |
 Actinogen Medical (ASX: ACW)ACW · ASX | 1 asset: 1 Ph 3 | EmestedastatPhase 2/3 · Alzheimer's DiseasePartial signal | None on record |
 Actio Biosciences, Inc.Private | 1 asset: 1 Ph 2 | ABS-1230Phase 2 · Epilepsy | Dec 2026ABS-1230 · Phase 1 |
 Acumen PharmaceuticalsABOS · Nasdaq | 1 asset: 1 Ph 2 | SabirnetugPhase 2 · Alzheimer's DiseasePartial signal | None on record |
 AdAlta1AD · ASX | 1 asset: 1 Ph 1 | AD-214Phase 1 · Chronic Kidney DiseasePartial signal | None on record |
 Adamas PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record |
 Addex TherapeuticsPrivate | 1 asset: 1 Ph 3 | Dipraglurant (ADX48621)Phase 2/3 · Parkinson's DiseasePartial signal | None on record |
 AddimmunePrivate | 1 asset: 1 Ph 1 | AGT103-TPhase 1 · HIVWeak signal | None on record |
 Adiso TherapeuticsPrivate | 1 asset: 1 Ph 1 | ADS051Phase 1 · Ulcerative ColitisPartial signal | None on record |
 Advanced BioDesignPrivate | 1 asset: 1 Ph 2 | ABD-3001Phase 1/2 · Acute Myeloid Leukemia | None on record |
 Advanz PharmaPrivate | 1 asset: 1 approved | Approved assets only | None on record |
 Advenchen LaboratoriesPrivate | 1 asset: 1 Ph 3 | AL8326Phase 3 · Non-Small Cell Lung Cancer | Dec 2027AL8326 · Phase 1 |
 Advesya SASPrivate | 1 asset: 1 Ph 2 | CCTx-001Phase 1/2 · Acute Myeloid Leukemia | Jul 2027CCTx-001 · Phase 1/2 |
 Aelix TherapeuticsPrivate | 1 asset: 1 Ph 2 | HTI vaccine (ChAdOx1.HTI/MVA.HTI)Phase 2 · HIVPartial signal | None on record |
| 1 asset: 1 Ph 2 | AV078Phase 2 · Epilepsy | 1 Sep 2027AV078 · Phase 2 | |
 Affini-T Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | AFNT-211Phase 1/2 · Non-Small Cell Lung Cancer | None on record |
 AgeneBioPrivate | 1 asset: 1 Ph 3 | AGB101Phase 2/3 · Alzheimer's DiseasePartial signal | None on record |
 Agepha PharmaPrivate | 1 asset: 1 approved | Approved assets only | None on record |
 Agomab Therapeutics NVAGMB · Nasdaq | 1 asset: 1 Ph 2 | ontunisertibPhase 2 · Fibrostenosing Crohn's Disease | None on record |
 Agyany Pharma LtdPrivate | 1 asset: 1 Ph 3 | AmbroxolPhase 3 · Parkinson's DiseasePartial signal | None on record |
 Ainos, Inc.AIMD · Nasdaq | 1 asset: 1 other | Interferon alfa (Veldona)Oral Warts in HIV Patients | None on record |
 Alar Pharmaceuticals6785 · TPEx | 1 asset: 1 Ph 1 | ALA-3000Phase 1 · Major Depressive DisorderPartial signal | None on record |
 Alaunos Therapeutics, Inc.TCRT · Nasdaq | 1 asset: 1 Ph 2 | DarinaparsinPhase 2 · Peripheral T-Cell Lymphoma | None on record |
 Aldeyra TherapeuticsALDX · Nasdaq | 1 asset: 1 Ph 3 | reproxalapPhase 3 · Dry Eye Disease | None on record |
 Alebund Pharmaceuticals9637 · HKEX | 1 asset: 1 Ph 3 | AP301 (fiber-iron phosphate binder)Phase 3 · Chronic Kidney DiseasePartial signal | None on record |
| 1 asset: 1 Ph 3 | EculizumabPhase 3 · HypertensionWeak signal | 7 Dec 2026Eculizumab · Phase 3 | |
 AlfasigmaPrivate | 1 asset: 1 Ph 3 | filgotinibPhase 3 · Rheumatoid ArthritisReliable signal | Jun 2027filgotinib · Phase 3 |
 Aligos TherapeuticsALGS · Nasdaq | 1 asset: 1 Ph 2 | ALG-055009Phase 2 · Metabolic Dysfunction-Associated Steatohepatitis | None on record |
 AllRock BioPrivate | 1 asset: 1 Ph 2 | ROC-101Phase 2 · Hypertension | Mar 2027ROC-101 · Phase 2 |
 Allarity Therapeutics, Inc.ALLR · Nasdaq | 1 asset: 1 Ph 2 | stenoparibPhase 2 · Ovarian Cancer | Mar 2027stenoparib · Phase 2 |
 Allodynic Therapeutics, LLCPrivate | 1 asset: 1 Ph 3 | Naltrexone/Acetaminophen (ALLOD-2)Phase 2/3 · Migraine | None on record |
 Allyx TherapeuticsPrivate | 1 asset: 1 Ph 1 | BMS-984923Phase 1 · Alzheimer's DiseasePartial signal | None on record |
 Alpha Cognition Inc.ACOG · Nasdaq | 1 asset: 1 approved | Approved assets only | Apr 2027Benzgalantamine · Approved |
 Alphyn BiologicsPrivate | 1 asset: 1 Ph 2 | zabalafinPhase 2 · Atopic Dermatitis | None on record |
 Alterome Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | ALTA3263Phase 1 · Non-Small Cell Lung Cancer | May 2029ALTA3263 · Phase 1 |
 AltimmuneALT · Nasdaq | 1 asset: 1 Ph 3 | pemvidutidePhase 3 · MASH / NASHPartial signal | 30 Sep 2027pemvidutide · Phase 2 |
 AltruBioPrivate | 1 asset: 1 Ph 2 | ALTB-268Phase 2 · Ulcerative Colitis | None on record |
 Alzamend NeuroALZN · Nasdaq | 1 asset: 1 Ph 2 | AL001Phase 1/2 · Alzheimer's Disease | Dec 2026AL001 · Phase 1/2 |
 AlzeCure PharmaPrivate | 1 asset: 1 Ph 1 | ACD856Phase 1 · Alzheimer's DiseasePartial signal | None on record |
 AlzheonPrivate | 1 asset: 1 Ph 3 | ValiltramiprosatePhase 3 · Alzheimer's DiseasePartial signal | None on record |
 Alzinova ABPrivate | 1 asset: 1 Ph 1 | ALZ-101Phase 1 · Alzheimer's DiseasePartial signal | None on record |
 Amandala Neuro LimitedPrivate | 1 asset: 1 Ph 2 | ELE-101Phase 1/2 · Major Depressive Disorder | None on record |
 Amarin CorporationAMRN · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record |
 Amicus TherapeuticsPrivate | 1 asset: 1 approved | Approved assets only | 31 Dec 2026Migalastat · Phase 3 |
 AmorepacificPrivate | 1 asset: 1 Ph 3 | asivatrepPhase 3 · Atopic DermatitisReliable signal | None on record |
 Amphista Therapeutics LtdPrivate | 1 asset: 1 Ph 1 | AMX-883Phase 1 · Acute Myeloid Leukemia | 4 Dec 2028AMX-883 · Phase 1 |
 Amylyx Pharmaceuticals, Inc.AMLX · Nasdaq | 1 asset: 1 Ph 3 | avexitidePhase 3 · Post-Bariatric Hypoglycemia | None on record |
 AnGes4563 · TSE | 1 asset: 1 Ph 3 | Beperminogene perplasmid (HGF plasmid)Phase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | None on record |
 AnaCardio ABPrivate | 1 asset: 1 Ph 2 | AC01Phase 2 · Heart FailurePartial signal | 30 Jul 2028AC01 · Phase 2 |
 AnaptysBioANAB · Nasdaq | 1 asset: 1 Ph 2 | RosnilimabPhase 2 · Rheumatoid Arthritis | None on record |
 Anbogen Therapeutics, Inc.7784 · TPEx | 1 asset: 1 Ph 2 | ABT-101Phase 1/2 · Non-Small Cell Lung Cancer | Nov 2026ABT-101 · Phase 1/2 |
 Angel PharmaceuticalsPrivate | 1 asset: 1 Ph 3 | CPI-006Phase 3 · Non-Small Cell Lung CancerWeak signal | None on record |
| 1 asset: 1 Ph 1 | Anhui HygeianCells EE001Phase 1 · Heart FailureWeak signal | None on record | |
 Ankyra Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | Tolododekin AlfaPhase 1 · Non-Small Cell Lung Cancer | Apr 2027Tolododekin Alfa · Phase 1 |
 Annovis Bio (NYSE American: ANVS)ANVS · NYSE American | 1 asset: 1 Ph 3 | BuntanetapPhase 3 · Alzheimer's DiseasePartial signal | Dec 2027Buntanetap · Phase 3 |
 Antag TherapeuticsPrivate | 1 asset: 1 Ph 2 | AT-7687Phase 2 · Obesity | Feb 2027AT-7687 · Phase 2 |
 Antengene Corporation Limited6996 · HKEX | 1 asset: 1 approved | Approved assets only | Dec 2026Selinexor · Phase 2/3 |
 Anterogen065660 · KOSDAQ | 1 asset: 1 Ph 3 | Cupistem / ALLO-ASCPhase 3 · Crohn's DiseaseWeak signal | None on record |
 Anwita Biosciences, Inc.Private | 1 asset: 1 Ph 1 | AWT020Phase 1 · Non-Small Cell Lung Cancer | 30 Apr 2028AWT020 · Phase 1 |
 Apellis PharmaceuticalsPrivate | 1 asset: 1 Ph 3 | PegcetacoplanPhase 3 · Chronic Kidney Disease | 25 Jun 2027Pegcetacoplan · Phase 2 |
| 1 asset: 1 Ph 2 | MetacavirPhase 2 · Chronic Hepatitis B | None on record | |
 AplagonPrivate | 1 asset: 1 Ph 2 | APACPhase 2 · Atherosclerotic Cardiovascular Disease | 30 Jun 2027APAC · Phase 2 |
| 1 asset: 1 Ph 2 | AP-472Phase 2 · Parkinson's Disease | 3 Sep 2027AP-472 · Phase 2 | |
 Aptabio Therapeutics293780 · KOSDAQ | 1 asset: 1 Ph 2 | APX-115Phase 2 · Type 2 DiabetesPartial signal | 30 Jun 2027APX-115 · Phase 2 |
 Araclon Biotech (Grifols)Private | 1 asset: 1 Ph 2 | ABvac40Phase 2 · Alzheimer's DiseasePartial signal | None on record |
 Arbutus BiopharmaABUS · Nasdaq | 1 asset: 1 Ph 2 | AB-101Phase 1/2 · Systemic Lupus Erythematosus | None on record |
 Arcutis BiotherapeuticsARQT · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record |
 ArdelyxARDX · Nasdaq | 1 asset: 1 approved | Approved assets only | 26 Feb 2027Tenapanor · Phase 3 |
 Arecor LimitedAREC · AIM | 1 asset: 1 Ph 1 | AT278Phase 1 · Type 2 DiabetesPartial signal | None on record |
 Areteia TherapeuticsPrivate | 1 asset: 1 Ph 3 | dexpramipexolePhase 3 · AsthmaPartial signal | None on record |
 AriBioPrivate | 1 asset: 1 Ph 3 | AR1001Phase 3 · Alzheimer's DiseasePartial signal | None on record |
 Arog Pharmaceuticals, Inc.Private | 1 asset: 1 Ph 3 | CrenolanibPhase 3 · Acute Myeloid Leukemia | None on record |
 Aromics TherapeuticsPrivate | 1 asset: 1 Ph 1 | AROG4-01Phase 1 · Non-Small Cell Lung Cancer | None on record |
 Artery TherapeuticsPrivate | 1 asset: 1 Ph 1 | CS6253Phase 1 · Alzheimer's DiseasePartial signal | None on record |
 Artgen BiotechABIO · MOEX | 1 asset: 1 Ph 3 | NeovasculgenPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
 Asher Biotherapeutics, Inc.Private | 1 asset: 1 Ph 1 | AB248Phase 1 · Non-Small Cell Lung Cancer | None on record |
 Asieris Pharmaceuticals688176 · SSE STAR Market | 1 asset: 1 Ph 1 | APL-1401Phase 1 · Ulcerative ColitisPartial signal | None on record |
 AskBioPrivate | 1 asset: 1 Ph 2 | AB-1005Phase 2 · Parkinson's DiseaseWeak signal | 30 Apr 2028AB-1005 · Phase 2 |
 Aspen NeurosciencePrivate | 1 asset: 1 Ph 1 | ANPD001Phase 1 · Parkinson's Disease | 30 Mar 2027ANPD001 · Phase 1 |
 Assembly BiosciencesASMB · Nasdaq | 1 asset: 1 Ph 1 | ABI-5366Phase 1 · Genital Herpes | None on record |
 Atavistik Bio, Inc.Private | 1 asset: 1 Ph 2 | ATV-1601Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | Dec 2027ATV-1601 · Phase 1/2 |
 Athos TherapeuticsPrivate | 1 asset: 1 Ph 2 | ATH-063Phase 2 · Ulcerative ColitisPartial signal | 14 Dec 2028ATH-063 · Phase 2 |
 Aulos Bioscience, Inc.Private | 1 asset: 1 Ph 2 | AU-007Phase 1/2 · Non-Small Cell Lung Cancer | 28 Feb 2027AU-007 · Phase 1/2 |
Auricula Biosciences Inc.Private | 1 asset: 1 Ph 2 | WEF-001Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2028WEF-001 · Phase 1/2 |
| 1 asset: 1 Ph 1 | AUR107Phase 1 · Non-Small Cell Lung Cancer | Jan 2027AUR107 · Phase 1 | |
 Auron Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | AUTX-703Phase 1 · Acute Myeloid Leukemia | Apr 2027AUTX-703 · Phase 1 |
 AusperBioPrivate | 1 asset: 1 Ph 2 | AHB-171Phase 2 · Chronic Hepatitis B | 8 Oct 2027AHB-171 · Phase 1 |
 Autobahn TherapeuticsPrivate | 1 asset: 1 Ph 2 | ElunetiromPhase 2 · Major Depressive Disorder | None on record |
 Autolus Therapeutics plcAUTL · Nasdaq | 1 asset: 1 approved | Approved assets only | Sep 2027obecabtagene autoleucel · Phase 1 |
 Avalyn Pharma Inc.AVLN · Nasdaq | 1 asset: 1 Ph 2 | AP01Phase 2 · Rheumatoid Arthritis | Jun 2027AP01 · Phase 2 |
 AvenCell Europe GmbHPrivate | 1 asset: 1 Ph 1 | Allo-RevCAR01-TPhase 1 · Acute Myeloid Leukemia | May 2027Allo-RevCAR01-T · Phase 1 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).